SEC Form 6-K filed by Chemomab Therapeutics Ltd.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

 

FORM 6-K

 

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934

 

For the month of October 2024

 

Commission File Number 001-38807

 

CHEMOMAB THERAPEUTICS LTD.
(Translation of registrant’s name into English)

 

Kiryat Atidim, Building 7, Tel-Aviv, Israel

(Address of principal executive offices)

 

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.

 

Form 20-F ☒      Form 40-F ☐

 

 

EXPLANATORY NOTE

 

Chemomab Therapeutics Ltd. (the “Company”) hereby furnishes the following documents:

 

 

 

This Form 6-K is incorporated by reference into the Company’s Registration Statements on Form F-3 (File No. 333-281750 and No. 333-275002) and Form S-8 (File No. 333-259489 and No. 333-266868).

- 2 -

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

 

- 3 -

---